Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
Authors
Keywords
Diabetes, Fibrosis, Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Sodium-glucose co-transporter 2 inhibitors, Steatosis
Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 907, Issue -, Pages 174272
Publisher
Elsevier BV
Online
2021-06-17
DOI
10.1016/j.ejphar.2021.174272
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combined EXENatide and DApagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycemic control in patients with type 2 diabetes mellitus treated with metformin – EXENDA , a 24 week, prospective, randomized, placebo‐controlled pilot trial
- (2021) Jürgen Harreiter et al. DIABETES OBESITY & METABOLISM
- Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
- (2021) Narjes Nasiri-Ansari et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
- (2021) Suetonia C Palmer et al. BMJ-British Medical Journal
- Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- (2021) Haleh Chehrehgosha et al. Diabetes Therapy
- Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
- (2021) Hiroaki Seino Diabetes Therapy
- Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
- (2021) Masato Yoneda et al. BMJ Open Diabetes Research & Care
- The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway
- (2021) Ziyu Meng et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis–associated liver tumors in a novel murine model
- (2021) Naoki Yoshioka et al. BIOMEDICINE & PHARMACOTHERAPY
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis
- (2020) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Effects of SGLT2 Inhibitors on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Meta‐Analysis of Randomized Controlled Trials
- (2020) Baodi Xing et al. Journal of Diabetes Investigation
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Drug Therapy in Obesity: A Review of Current and Emerging Treatments
- (2020) David M. Williams et al. Diabetes Therapy
- Metabolic liver disease in diabetes – From mechanisms to clinical trials
- (2020) Bedair Dewidar et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)
- (2020) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2020) Hoda Taheri et al. ADVANCES IN THERAPY
- Effect of sodium-glucose Cotransporter 2 inhibitors on cardiovascular and kidney outcomes – Systematic review and meta-analysis of randomized placebo-controlled trials
- (2020) Husam M. Salah et al. AMERICAN HEART JOURNAL
- Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
- (2020) Francisca dos Santos Coelho et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease
- (2020) Evangelia Makri et al. ARCHIVES OF MEDICAL RESEARCH
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD
- (2020) Yusuf Yilmaz et al. Expert Review of Gastroenterology & Hepatology
- Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
- (2020) David C Wheeler et al. Lancet Diabetes & Endocrinology
- Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
- (2020) Alessandro Mantovani et al. Metabolites
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
- (2019) Peter J. Eddowes et al. GASTROENTEROLOGY
- Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
- (2019) Lee-Lee Lai et al. DIGESTIVE DISEASES AND SCIENCES
- The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
- (2019) Aino Latva-Rasku et al. DIABETES CARE
- Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block
- (2019) Vasilios G. Athyros et al. Current Vascular Pharmacology
- Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
- (2019) Sabine Kahl et al. DIABETES CARE
- Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress
- (2019) Tamiris Ingrid Petito-da-Silva et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
- (2019) David M. Williams et al. Diabetes Therapy
- OPTN/SRTR 2016 Annual Data Report: Liver
- (2018) W. R. Kim et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
- (2018) Jan W. Eriksson et al. DIABETOLOGIA
- Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation
- (2018) Soad L. Kabil et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Pharmacotherapy of type 2 diabetes: An update
- (2018) Jagriti Upadhyay et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis
- (2018) Alessandro Mantovani et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH
- (2018) Kumiko Shiba et al. Scientific Reports
- Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease
- (2018) Masanori Shimizu et al. DIABETES OBESITY & METABOLISM
- Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
- (2018) Naveed Sattar et al. DIABETOLOGIA
- Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
- (2018) Zobair Younossi et al. HEPATOLOGY
- Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
- (2018) Kenneth Cusi et al. DIABETES OBESITY & METABOLISM
- Sodium-glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter-organ crosstalk
- (2018) Jin Hee Kim et al. DIABETES OBESITY & METABOLISM
- Impact of SGLT2 inhibitor to histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus
- (2018) Norio Akuta et al. HEPATOLOGY RESEARCH
- Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes
- (2018) Ji-Won Kim et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
- (2018) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
- (2017) Zobair Younossi et al. Nature Reviews Gastroenterology & Hepatology
- Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
- (2017) Satish K. Garg et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
- (2017) Liang Xu et al. EBioMedicine
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
- (2017) Christoph Wanner et al. CIRCULATION
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- Emerging and future therapies for nonalcoholic steatohepatitis in adults
- (2016) Gesthimani Mintziori et al. EXPERT OPINION ON PHARMACOTHERAPY
- Insulin Resistance is Associated With Significant Liver Fibrosis in Chronic Hepatitis C Patients
- (2016) Suhag Patel et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
- (2016) Giovanni Targher et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Nonalcoholic fatty future disease
- (2016) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Pharmacological management of nonalcoholic fatty liver disease
- (2016) Diana Barb et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
- (2016) Teruo Jojima et al. Diabetology & Metabolic Syndrome
- The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
- (2016) Yasushi Honda et al. PLoS One
- Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
- (2016) Chikara Komiya et al. PLoS One
- Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis
- (2016) Shunquan Wu et al. Scientific Reports
- Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor
- (2015) Pablo Lapuerta et al. Diabetes & Vascular Disease Research
- Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport
- (2015) Sunder Mudaliar et al. DIABETES CARE
- Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
- (2015) V. Salem et al. DIABETES OBESITY & METABOLISM
- Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats
- (2015) Yuka Hayashizaki-Someya et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
- (2015) Eduardo Vilar-Gomez et al. GASTROENTEROLOGY
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
- (2015) Paul Angulo et al. GASTROENTEROLOGY
- Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up
- (2015) Mattias Ekstedt et al. HEPATOLOGY
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
- (2015) Shirong Qiang et al. Diabetology & Metabolic Syndrome
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study
- (2013) D. Polidori et al. DIABETES CARE
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease
- (2013) Jennifer E. Lambert et al. GASTROENTEROLOGY
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
- (2013) William T Cefalu et al. LANCET
- Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease
- (2013) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Improved glycemic control in mice lacking Sglt1 and Sglt2
- (2012) David R. Powell et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
- (2012) Naga Chalasani et al. HEPATOLOGY
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
- (2011) R. Grempler et al. DIABETES OBESITY & METABOLISM
- Biology of Human Sodium Glucose Transporters
- (2011) Ernest M. Wright et al. PHYSIOLOGICAL REVIEWS
- Nonalcoholic Fatty Liver Disease: The Pathogenetic Roles of Insulin Resistance and Adipocytokines
- (2009) Stergios Polyzos et al. CURRENT MOLECULAR MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started